{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:57:36Z","timestamp":1771297056631,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["23719"],"award-info":[{"award-number":["23719"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2016-02361134"],"award-info":[{"award-number":["GR-2016-02361134"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR -M4C2"],"award-info":[{"award-number":["PNRR -M4C2"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clon.2023.12.005","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T15:35:08Z","timestamp":1702654508000},"page":"87-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A\u00a0Meta-analysis of Randomised Trials"],"prefix":"10.1016","volume":"36","author":[{"given":"V.","family":"Merz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Zecchetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Quinzii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Frisinghelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Salati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Melisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2023.12.005_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/hep.31200","article-title":"Insights into the origin of intrahepatic cholangiocarcinoma from mouse models","volume":"72","author":"Zhu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.clon.2023.12.005_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clon.2023.12.005_bib3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/liv.13998","article-title":"Classifications and misclassification in cholangiocarcinoma","volume":"39","author":"Cardinale","year":"2019","journal-title":"Liver Int"},{"issue":"Suppl. 1","key":"10.1016\/j.clon.2023.12.005_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.clon.2023.12.005_bib5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clon.2023.12.005_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clon.2023.12.005_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2023.12.005_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clon.2023.12.005_bib10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2023.12.005_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib12","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/fon-2020-0726","article-title":"Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma","volume":"17","author":"Merz","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clon.2023.12.005_bib16","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib17","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib20","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib22","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.2147\/OTT.S105587","article-title":"Onivyde for the therapy of multiple solid tumors","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clon.2023.12.005_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1054-3589(08)61131-X","article-title":"Preclinical and clinical development of camptothecins","volume":"29B","author":"Costin","year":"1994","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.clon.2023.12.005_bib24","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2023.12.005_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40487-022-00215-2","article-title":"Liposomal irinotecan shows a larger therapeutic index than non-liposomal irinotecan in patient-derived xenograft models of pancreatic cancer","volume":"11","author":"Barbier","year":"2023","journal-title":"Oncol Ther"},{"key":"10.1016\/j.clon.2023.12.005_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2217\/pgs.10.95","article-title":"Irinotecan pharmacogenomics","volume":"11","author":"Marsh","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clon.2023.12.005_bib27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"issue":"suppl_7","key":"10.1016\/j.clon.2023.12.005_bib29","first-page":"S563","article-title":"Nal-IRI and 5-FU\/LV compared to 5-FU\/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC \u2013 AIO-HEP-0116)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.clon.2023.12.005_bib31","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clon.2023.12.005_bib32","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clon.2023.12.005_bib33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"suppl_7","key":"10.1016\/j.clon.2023.12.005_bib34","first-page":"S1464","article-title":"Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal irinotecan (NAL-IRI) plus fluorouracil (5-FU)\/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2023.12.005_bib36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2023.12.005_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA661","article-title":"NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil\/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"41","author":"Wainberg","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1186\/s12885-019-6142-y","article-title":"Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study","volume":"19","author":"Perkhofer","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2023.12.005_bib39","doi-asserted-by":"crossref","first-page":"S1282","DOI":"10.1016\/j.annonc.2021.08.2082","article-title":"LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group","volume":"32","author":"Perkhofer","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/1471-2407-8-374","article-title":"Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study","volume":"8","author":"Kim","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2023.12.005_bib41","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","article-title":"Second-line therapies in advanced biliary tract cancers","volume":"21","author":"Tella","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clon.2023.12.005_bib43","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(21)00664-1","article-title":"Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer","volume":"23","author":"Rizzo","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib44","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cpt.720","article-title":"Population pharmacokinetics of liposomal irinotecan in patients with cancer","volume":"102","author":"Adiwijaya","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clon.2023.12.005_bib45","doi-asserted-by":"crossref","first-page":"513-27","DOI":"10.1111\/cas.14264","article-title":"Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study","volume":"111","author":"Bang","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clon.2023.12.005_bib46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(13)62296-5","article-title":"Increasing value and reducing waste: addressing inaccessible research","volume":"383","author":"Chan","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2023.12.005_bib47","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1158\/1078-0432.CCR-20-0395","article-title":"Plasma IL8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer","volume":"26","author":"Merz","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2023.12.005_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00280-020-04094-0","article-title":"First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer","volume":"86","author":"Taghizadeh","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clon.2023.12.005_bib49","first-page":"52","article-title":"Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers","volume":"16","author":"Allo","year":"2022","journal-title":"Mol Clin\u00a0Oncol"},{"key":"10.1016\/j.clon.2023.12.005_bib50","doi-asserted-by":"crossref","first-page":"TPS593","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS593","article-title":"Phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)","volume":"38","author":"Weinberg","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523004818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523004818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:53:31Z","timestamp":1760543611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655523004818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0936655523004818"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2023.12.005","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A\u00a0Meta-analysis of Randomised Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2023.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}